Genetically Modified Cell-based Therapy Naming Scheme

Recently there have been revisions in naming genetically modified cell-based therapies. In the past, these types of therapies were named as cellular therapies using the infix "-gen-" for cells that were transduced with a gene.

The Office of Cellular, Tissue and Gene Therapies (OCTGT) group of the FDA, the USAN Council and the INN agreed to use a 2-word naming scheme for genetically modified cell-based therapies. The first word is to be the same as the gene therapy first word for the gene. The second word suffix is "-cel" and a cell type infix is included before the "-cel" ending.

As shown below, both words will only contain one infix.

First Word: Corresponds to the Gene Component

Prefix: Random to contribute euphonious and distinctive name.

Infix: To identify the gene using existing infixes for biological products or using a similar infix for the protein for which the gene codes:

-ald-  adrenoleukodystrophy (ALD) protein
-beglo-  ?A-t87Q-globin
-bermin-  vascular endothelial growth factor
-cabta-  cell expressed antibody and T cell activation
-cima-  cytosine deaminase
-ermin-  growth factor
-etid-  eczema-throbocytopenia-immunodeficiency syndrome
-far-  interferon

URL: https://www.ama-assn.org/about/united-states-adopted-names/genetically-modified-cell-based-therapy-naming-scheme

Copyright 1995 - 2021 American Medical Association. All rights reserved.
-fermin-  fibroblast growth factor
-kin-     interleukins
-lim-     immunomodulator
-lip-     human lipoprotein lipase
-mul-     multiple genes
-naco-    coagulation factor IX
-nad-     NADH dehydrogenase
-nermin-  tumor necrosis factor (TNF)
-octoco-  coagulation factor VIII
-pap-     human papilloma virus
-papkino- human papilloma virus and IL-2
-permin-  hepatocyte growth factor
-repi-    REP-1 gene
-reti-    retinal pigment
-semn-    SMN
-stim-    colony stimulating factor
-tima-    thymidine kinase
-tusu-    tumor suppression

Suffix: - (a vowel) gene: e.g., -(o)gene

Second Word: Corresponds to the Vector and Cell Component

Prefix: Random to contribute euphonious and distinctive name.

URL: https://www.ama-assn.org/about/united-states-adopted-names/genetically-modified-cell-based-therapy-naming-scheme
Copyright 1995 - 2021 American Medical Association. All rights reserved.
**Infix:** Cell type; reference USAN/INN infix for cell type:

- **-ada-**  adenosine deaminase
- **-co(n)-**  chondrocytes
- **-den-**  dendritic cells
- **-end(o)-**  endothelial cells
- **-ep(a)-**  hepatocytes
- **-fi(b)-**  fibroblasts
- **-isle-**  islet cells
- **-ker(a)-**  keratinocytes
- **-leu-**  lymphocytes/monocytes/ APC (white cells)
- **-mestro-**  mesenchymal stromal cells
- **-mio(b)-**  myoblasts
- **-ova-**  ovary cells
- **-pla(c)-**  placental cells
- **-ren-**  renal tubular cells
- **-ret-**  retinal cells
- **-tem-**  stem cells
- **-tesi-**  testis cells
- **-tu-**  tumor cells
- **-ubi-**  umbilical cord cells (formerly -cor-)
- **-ur-**  urothelial cells

**Suffix:** -cel